Company Focus
GSK
Latest GSK News
Biotechnology
Chinese drugmaker Hansoh Pharma says its GSK-partnered antibody-drug conjugate risvutatug rezetecan, or Ris-Rez, has met the primary endpoint of overall survival in a pivotal Phase III trial in small cell lung cancer. 10 July 2026
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing atacicept and other targeted therapies for serious immunological and kidney diseases with high unmet medical need.
Latest News & Features of interest to GSK
Biotechnology
The US Food and Drug Administration (FDA) has approved pharma giant Pfizer and Japanese drugmaker Astellas Pharma’s Padcev (enfortumab vedotin-ejfv) plus Merck & Co’s Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment for adults with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility. 10 July 2026
Biotechnology
The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all existing indications of Sarclisa intravenous (IV) formulation. 10 July 2026
Biotechnology
Chinese drugmaker Hansoh Pharma says its GSK-partnered antibody-drug conjugate risvutatug rezetecan, or Ris-Rez, has met the primary endpoint of overall survival in a pivotal Phase III trial in small cell lung cancer. 10 July 2026
Pharmaceutical
The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance rejecting routine National Health Service (NHS) use of Amgen’s Lumykras (sotorasib) for previously treated KRAS G12C-mutated advanced non-small-cell lung cancer. 10 July 2026
Biotechnology
GSK has terminated its neurodegeneration collaboration with Alector, ending an alliance established five years ago around two experimental antibodies. The decision follows clinical setbacks in frontotemporal dementia and early Alzheimer’s disease, which left neither of the partnered programmes in active development. 10 July 2026
Biotechnology
The China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for Padcev (enfortumab vedotin) in combination with Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) as neoadjuvant treatment (before surgery), and then continued after cystectomy (surgery) as adjuvant treatment (after surgery), for adults with muscle-invasive bladder cancer (MIBC), regardless of their eligibility for cisplatin-containing chemotherapy. 9 July 2026
Biotechnology
Anglo-Swedish pharma major AstraZeneca has licensed ex-China rights to TQC3721, an investigational inhaled PDE3/4 inhibitor for chronic respiratory diseases, from Hong Kong-listed Sino Biopharmaceutical. 9 July 2026
Pharmaceutical
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (8 July 2026) approved Jascayd (nerandomilast) to treat adults with a lung disease called idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). 8 July 2026
Biotechnology
US precision oncology biotech Stipple Bio has appointed Roland Gendron as chief business officer as it prepares to move lead candidate STP-100 into early clinical studies. 8 July 2026
Pharmaceutical
Helix has signed a multi-year agreement with AstraZeneca giving the Anglo-Swedish drugmaker access to its GenoSphere clinico-genomic cohorts as it looks to sharpen research across a wide range of disease areas. 8 July 2026
Latest In Brief for GSK
Pharmaceutical
Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions. 7 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze